Design Therapeutics, Inc. (DSGN) Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Design Therapeutics, Inc. NASDAQ:DSGN Healthcare · Biotechnology
Mkt Cap $668.37M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference
Design Therapeutics (DSGN) announced management will participate in a fireside chat at the 2026 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 9, 2026, at 2:45 p.m. ET in New York.
A live webcast will be available via the company's investor relations website, with the archive accessible for at least 30 days following the presentation.
The release contains no new clinical or financial data; it restates the pipeline of GeneTAC programs, including DT-216P2 for Friedreich ataxia, DT-168 for Fuchs endothelial corneal dystrophy, DT-818 for myotonic dystrophy type-1, and a Huntington's disease program.
• 1mo ago AI analysis › Press Release ⚠ 1
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
Design Therapeutics reported Q2 financial results featuring a net loss of $20.2 million and a solid cash position of $207.4 million, which management believes funds operations into the future.
The company provided a clinical update on its RESTORE-FA trial for Friedreich ataxia, modifying the study to support registrational plans with 12-week data expected in Q1 2027, and initiated dosing in a Phase 1 trial for DT-818 in myotonic dystrophy.
While progress continues across the GeneTAC portfolio, the company disclosed that data for the DT-168 program in Fuchs dystrophy has been delayed to 2027 due to supply issues with eye droppers.
• 2mo ago AI analysis › Press Release
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
Design Therapeutics announced the initiation of patient dosing in a Phase 1 multiple-ascending dose (MAD) trial of DT-818 for adults with myotonic dystrophy type-1 (DM1).
DT-818 is a GeneTAC(®) small molecule designed to selectively reduce transcription of the mutant DMPK allele to address the underlying genetic cause of the disease.
The company anticipates reporting data from this study in 2027.
• 4mo ago AI analysis › Press Release
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
Design Therapeutics management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026.
The session is scheduled for 1:25 p.m. ET in New York and will be available via live webcast on the company’s investor relations website.
The release includes standard boilerplate descriptions of the company’s GeneTAC platform and clinical programs for Friedreich ataxia, Fuchs endothelial corneal dystrophy, myotonic dystrophy, and Huntington’s disease.
• 5mo ago AI analysis › Press Release ● Major ⚠ 2
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
Design Therapeutics reported positive Phase 1/2 data for DT-216P2 in Friedreich Ataxia, showing dose-dependent clinical improvements and biomarker activity after four weeks of IV dosing.
At the 1 mpk dose, patients saw a 6.4-point improvement in mFARS and a 2.7-point improvement in Upright Stability Score, alongside >5-point reductions in fatigue.
Biomarker data confirmed mechanistic activity, with whole blood FXN mRNA rising 65% and muscle FXN mRNA rising 42% from baseline.
The company plans to advance DT-216P2 toward registrational development, with an update expected in Q4 2026.
• 5mo ago AI analysis › Press Release
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
Design Therapeutics will announce data from its ongoing Phase 1/2 RESTORE-FA trial of DT-216P2 for Friedreich’s ataxia on Monday, May 18, 2026.
Management will host a conference call and webcast at 8:00 a.m. ET to review the results.
The live webcast will be available on the company’s website and archived for at least 30 days.
• 5mo ago AI analysis › Press Release
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
Design Therapeutics reported a Q1 2026 net loss of $17.6 million, with R&D expenses reaching $14.4 million and G&A expenses at $5.3 million.
The company ended the quarter with $222.8 million in cash and securities, a balance expected to fund planned operations into 2029.
Pipeline updates indicate ongoing dosing in the RESTORE-FA trial for DT-216P2, with biomarker data anticipated in the second half of 2026, and the appointment of Dr. David Shapiro to the board of directors.
• 6mo ago AI analysis › 
